New EGA president promotes value and globalisation
12/10/2011 - Meeting today in Warsaw, the European Generic medicines Association’s Board announced the election of Gudbjorg Edda Eggertsdottir as its new President. Ms Eggertsdottir has been active in the generic medicines industry for over 30 years, witnessing the many challenges it has already faced on its way to becoming an essential part of the global healthcare offering.
The European Generic Medicines Association welcomes Commission’s revised proposals on information to patients
11/10/2011 - The European Generic medicines Association (EGA) welcomes the revised proposals on information to patients published today by the European Commission.
EGA member’s commitment regarding DCP slot booking launched at CMD(h) meeting
22/06/2011 - The European Generic medicines Association (EGA) officially launched the code of conduct on slot booking for Marketing Authorisation Applications (MAA) as the generic medicines industry’s contribution to the process of improving the functioning of the EU regulatory system.
Making Europe the medicines manufacturer of the world
17/06/2011 - Europe must seize on new opportunities to increase employment and create growth in the generic and biosimilar medicines markets. This was a key message delivered at the 17th Annual Conference of the European Generic medicines Association in Lisbon on 16-17 June 2011.
EGA 2011 Market Review: Price and Reimbursement Systems
10/5/2011 - This first part of the 2011 Market Review addresses 10 major topics, namely: Generic Medicines Pricing Systems, Tendering Systems, Reimbursement Systems, Patient Co-payments, Patient Use of Generic Medicines, Generic Medicines Prescribing, Generic Medicines Substitution...
Competitiveness of the EU biosimilar medicines industry
14/4/2011 - EGA calls for an EU industrial policy to enhance the competitiveness of the EU biosimilar medicines industry
EGA welcomes the european parliament vote on falsified medicines
16/2/2011 - EGA welcomes the european parliament vote on falsified medicines and anticipates an intense implementation phase
Improvements to the EU regulatory environment
25/1/2011 - Improvements to the EU regulatory environment will increase patient access to generic and biosimilar medicines and enhance competitiveness and competition
